A review of activity indices and end points for clinical trials in children with Crohn's disease

Inflammatory Bowel Diseases

Volumn 11, Issue 2, 2005, Pages 185-196

  Griffiths, Anne M ^a   Otley, Anthony R ^b   Hyams, Jeffrey ^c   Quiros, Antonio R ^d   Grand, Richard J ^e   Bousvaros, Athos ^e   Feagan, Brian G ^f   Ferry, George R ^g  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Izaak Walton Killam Hospital for Children   (Canada)

^c Farmington   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Clinical trails; Crohn's disease; Pediatrics

Indexed keywords

BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; PREDNISOLONE; PREDNISONE;

ADOLESCENT; ANTHROPOMETRY; BODY HEIGHT; CHILD; CLINICAL STUDY; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG RESPONSE; ENTERIC FEEDING; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; BIOASSAY; CHILD DEVELOPMENT; CHILD WELFARE; FEMALE; GASTROENTEROLOGY; HOSPITALIZATION; MALE; METHODOLOGY;

ADOLESCENT; CHILD; CHILD DEVELOPMENT; CHILD WELFARE; CLINICAL TRIALS; CROHN DISEASE; ENDPOINT DETERMINATION; FEMALE; GASTROENTEROLOGY; HUMANS; MALE; QUALITY OF LIFE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 18244395608     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200502000-00013     Document Type: Review

References (60)

1. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large population-based study in Sweden. Gastroenterology. 1991;100:350-358.
2. Marshall JK, Hilsden RJ. Environment and epidemiology of inflammatory bowel disease. In: Satsangi J, Sutherland LR, eds. Inflammatory Bowel Diseases. London, UK: Churchill Livingstone; 2003:17-28.
3. Sawczenko A, Sandhu B. Presenting features of inflammatory bowel disease in children. Arch Dis Child. 2003;88:995-1000.
4. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003; 143:525-531.
5. Griffiths AM. Specificities of inflammatory bowel disease in childhood. In: Hugot J.-P., ed. Best Practice & Research Clinical Gastroenterology. Amsterdam, The Netherlands: Elsevier Ltd.; 2004;18:509-523.
6. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn's disease. Gut. 1993;34:939-943.
7. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology. 1988;95:1523-1527.
8. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18:165-173.
9. Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373-380.
10. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993;105:681-691.
11. Murch SH. Inflammatory mediators and suppression of growth in paediatric chronic IBD. In: Tytgat GNJ, Bartelsman JFWM, van Deventer SJH, eds. Inflammatory Bowel Diseases. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1995.
12. Hyams JS, Wyzga N, Kreutzer DL, et al. Inhibition of bone formation in children with Crohn's disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289-295.
13. DeBenedetti F, Alonzi T, Moretta A. Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-growth factor I. J Clin Invest. 1997;99:643-650.
14. Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46:1-6.
15. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
16. Sandborn W, Feagan B, Hanauer S, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
17. Kitching A, Sackett D, Yusef S, et al. Approaches to Evaluating Evidence. London, UK: BMJ Books; 1998.
18. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch Dis Child. 1966;41:454-471.
19. Tanner JM Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317-329.
20. Tillmann V, Thalange NKS, Foster PJ, et al. The relationship between stature, growth and short-term changes in height and weight in normal prepubertal children. Pediatr Res. 1998;44:882-886.
21. Marshall WA. Evaluation of growth rate in height over periods of less than one year. Arch Dis Child. 1971;46:414-420.
22. Baumgartner RN, Roche AF, Himes JH. Incremental growth tables: supplementary to previously published charts. Am J Clin Nutr. 1986;43: 711-722.
23. Hermanussen M, Geiger-Benoit K, Burmeister J, et al. Periodical changes of short term growth velocity ("mini-growth spurts") in human growth. Ann Hum Biol. 1988;15:103-109.
24. Zollner E, Bonnici F. Assessment of growth-the role of knemometry. S Afr Med J. 1998;3:358-360.
25. Crofton PM, Kelnar CJH. Bone and collagen markers in paediatric practice. Int J Clin Pract. 1998;52:557-565.
26. Hyams JS, Moore RE, Leichtner AM, et al. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr. 1988;112:893-898.
27. Hyams JS, Moore RE, Leichtner AM, et al. Longitudinal assessment of type I procollagen in children with inflammatory bowel disease subjected to surgery. J Pediatr Gastroenterol Nutr. 1989;8:68-74.
28. Wolthers OD, Hansen M, Juul A, et al. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res. 1997;41:44-50.
29. Best W, Becktel J, Singleton J, et al. Development of a Crohn's disease activity index. Gastroenterology. 1976;70:439-444.
30. Hyams J, Ferry G, Mandel F, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
31. Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology. 1999;116:527-531.
32. Hyams J, Mandel F, Ferry G, et al. Relationship of common laboratory parameters to the activity of Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1992;14:216-222.
33. Kundhal P, Critch J, Zachos M, et al. Pediatric Crohn's disease activity index is responsive to short term change. J Pediatr Gastroenterol Nutr. 2003;36:83-89.
34. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn's disease activity index: usefulness in the practice setting. J Pediatr Gastroenterol Nutr. 2004;39(Suppl):0712.
35. Seidman E, Griffiths A, Jones A, et al. Semi-elemental diet versus prednisone in the treatment of acute Crohn's disease in children and adolescents. Gastroenterology. 1993;104:A778.
36. Griffiths AM, Seidman E, Issenman R. Elemental versus polymeric enteral nutrition in the treatment of active pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 2000;31:A291.
37. Escher JC. and the European Collaborative Pediatric IBD Research Group. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomised, double-blind, controlled, multicenter trial. Eur J Gastroenterol Hepatol. 2004;16:47-54.
38. Baldassano R, Braegger CP, Escher JC, et al. Infliximab therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838.
39. Seidman E, Jones A, Issenman R, et al. Cyclical exclusive enteral nutrition versus alternate day prednisone in maintaining remission of pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 1996;23:A344.
40. Markowitz J, Grancher K, Mandel F, et al. 6-mercaptopurine and prednisone therapy for newly diagnosed pediatric Crohn's disease: a prospective multicenter placebo-controlled clinical trial. Gastroenterology. 2000; 119:895-902.
41. Baldassano R. REACH trial: infliximab in the maintenance of remission in children with Crohn's disease (Unpublished).
42. de Dombal FT, Softley A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease; International Organisation for the Study of Inflammatory Bowel Disease. Gut. 1987; 28:474-481.
43. Sands BE, Steinhart AH, Lewis JD, et al. Optimal Crohn's disease activity index (CDAI) response criteria is defined by decrease ≥ 100 points. Gastroenterology. 2003;124:A206.
44. Guyatt GH, Deyo RA, Charlson M, et al. Responsiveness and validity in health status measurement. J Clin Epidemiol. 1989;42:403-408.
45. Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther. 2000;14:1419-1428.
46. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001;5:1-157.
47. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): 1. Conceptual framework and item selection. Med Care. 1992; 30:473-483.
48. McHorney CA, Ware JE Jr, Lu JF, et al. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
49. Landgraf JM, Ware J. The Child Health Questionnaire Manual. Boston, MA; 1996.
50. Patrick L, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217-S232.
51. Griffiths AM, Nicholas D, Smith C, et al. Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type. J Pediatr Gastroenterol Nutr. 1999;28: S46-S52.
52. Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;35:557-563.
53. Forget S, Issenman RM, Gold N, et al. Assessment of functional status in children and adolescents with inflammatory bowel disease (IBD). Gastroenterology. 1997;112:A974.
54. Forget S, Norman R, Issenman RM, et al. Health-related quality of life in pediatric inflammatory bowel disease: a comparison of parent and child reports. Gastroenterology. 1998;114:A977.
55. Forget S, Cawdron R, Issenman RM, et al. Validation of a disease specific health-related quality of life (HRQOL) instrument for pediatric inflammatory bowel disease (IBD). Gastroenterology. 1998;114:A978.
56. Guyatt G, Mitchell A, Irvine EJ, et al. Measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-810.
57. Richardson G, Griffiths AM, Miller V, et al. Quality of life in inflammatory bowel disease: a cross-cultural comparison of English and Canadian children. J Pediatr Gastroenterol Nutr. 2001;32:573-578.
58. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417-1432.
59. Loonen HJ, Grootenhuis MA, Last BF, et al. Measuring quality of life in children with inflammatory bowel disease: the IMPACT-II (NL). Qual Life Res. 2002;11:47-56.
60. Otley A, Griffiths AM, Hyams J, et al. IMPACT-II QOL Questionnaire: performance in new-onset pediatric IBD patients (The pediatric IBD collaborative registry). Gastroenterology. 2003;124(4, Suppl 1):A208.